pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-16-2 |
Genomic Coordinates | chr3: 160404745 - 160404825 |
Description | Homo sapiens miR-16-2 stem-loop |
Comment | This entry represents a second putative hairpin precursor sequence for miR-16, located on chromosome 3 (see also MIR:MI0000070). The sequence was previously named mir-16-3 here and in references . |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-16-2-3p | ||||||||||||||||||
Sequence | 53| CCAAUAUUACUGUGCUGCUUUA |74 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ANP32E | ||||||||||||||||||||
Synonyms | LANP-L, LANPL | ||||||||||||||||||||
Description | acidic nuclear phosphoprotein 32 family member E | ||||||||||||||||||||
Transcript | NM_001136478 | ||||||||||||||||||||
Other Transcripts | NM_001136479 , NM_030920 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ANP32E | |||||||||||||||||||||
3'UTR of ANP32E (miRNA target sites are highlighted) |
>ANP32E|NM_001136478|3'UTR 1 ATCATTCTAAGACCAGATTCTCTAATGTTTCTGGGTGTGCAATAGAGTGATCACATCTTTGTTTCTTCATGTACGATAGC 81 TATCCCTACAGAAGATAATGTGTAACTTTTTATAGGAAAAGTGTGGTTTTACTATTTTTGCCTTATCATTCCAAATAAGA 161 ACTAGTCTGTTAATGATCATATTGTATGTAGAGAAAAATTTTCATTGACTCCCATTGTGGAATTCCCTAGCAATTTATTT 241 AGACTTAATTTTTTAAATTCAAGCTTACTGTATTAGTCATTTTTAGCCCATAATTAAAACATGATCACTTTTACACAGGT 321 GTAGTATGGTGCATTTCATTCCTTATTTATAAATTAACTGAAATTACAGTTTGCTATAATATAAAATGACAATAGTCTCT 401 TGAGTGGTAAGTTGGTTATTTTTTTAGAGGTGATCCAGGAATCTTTAGTTTGAAGGCAGTTACCTTTTTTTTTTTTTTTT 481 TTTGACTAAGAGTGTTTGGTTGCTTTTTTGTCACAAGTAACTTGGAAAATAGAAGCAGAATAGTAAAGGTTCTATTCAGC 561 AACATAGTTCATGGATTTTGTGGAGGTTCTATTCAGTAATATGGTTCATGGATTTAGTGGTGACTGATAAGATTTTATTT 641 TTGAAGGAAAAATTGCTTATACTAAGTCCAGAGACATGCAGGTGAGCCCTTTTGTCAGGCTGCAAATCATGACATGCCGA 721 TGGTTGTTTATTTTGTTTTTAGGTGTGCATTCTTTTTCTTCTTAGCAATTCCTTTATGATCACCTTCCCTTCTTGTTTCA 801 CTCCCTCCCGCTCTCTCAAAAGGAACTTGGGAAACTTGTGAAACCCAGGAAAACCTTTAGTCTTATACCTCAACTACCTT 881 TCAGTCCTGTCTGGGTTTTAAATAAGTGAAGTAGAAGAAATTGAGTATTTTCTGACATAAGAATATATTATCAATACAGT 961 TTTATGCAGTAAGCTCTCCTTACCATAAATGTTTCTTGGTTGACAACATCTAAGACAATATTAGTGGGATGAAGAAAGAA 1041 AAGCAGGGGTGCTTTTGGAAGCAGTGTTAGTGTTCCTCAAAAGTCGGAACAATTGCCTGTTGATATATTAATAAGACATT 1121 AAAGTCAAATTTTAATGTTGGCCTCTCAAATGATTTGGATACCACTCTGCAAAGTATTTCTAACCTTTAATTCCCAGTTT 1201 TAAAACAGATATAATAATAGCATTTAATTGGAATATACTAGGCAGCTGGAAAAGTATTTGAAACTAAATTGACATTAAAA 1281 TTAAGATTTGTTTTCAAGTGGATGTCCATTAAAAGTAGAAAAATATTTGGGATAAGTGAGTGTGTGTTTCCTTACATGGC 1361 TACTAAATAAAATATAATGAGTATACAAGTATATCTCCTCTTTTGCTATGGAGGCTCCATGTTCAAGGCAATGGCTTTTT 1441 AAATCTTGGCTATCTAAAATTTTTTCCCTTTGTTTTGAATATTTGTAAGTTTTTAAGAAGTTAGTGTCAGCAAATTAATT 1521 GAAGTTATGCTTCTATACTGGGACATATTTAAATACTGAGTATAGTACTGCTGCTACTGCTTCTACAATGTAAAATGTAT 1601 GACTTGGTGTTTTAAAGTAAAAATTATGATGTTACTTGTGGAGAAACTAAAAATGTTGTACAACTGACCGAAAGAAAACC 1681 CTTGGGGATAAGTTTAGTGAGGGGATTGGAATCCCCAAAAAGATAACATTTTTCTTCTGCTTTTAAAAACTGAAATTCCC 1761 TGTTCTAGTTCCTAACAATTCTCATTACATACTATGCCAGATTACAAAATACTTATTTTTAAAATGAAATCTATATATTG 1841 ACTTTCTTATCAATCATCTTACTGTGCAATCAAAATTAGAGTACTTTGGTTTGAAAACAACACTTAGAGCCTCCAGATAA 1921 CTTTTAAGACTTATTTAGCTTTGTGGGTGGTATTTTCATGCAAATAAGTAAGGGTGGGTTTTATATTTTGTAGAAGTTTT 2001 CGGTCCTATTTTAATGCTCTTTGTATGGCAGTATGTATATATTGTGTTAAGTTCCTCAAGAATCTCCTTAAAAACTTTGA 2081 AGTTAATACTTTTGTGCAACTGTGTTTTGAATAAAGCCATGACAGTGTTAAAAACAAACAAAAAAATTTGCAGTACTCCT 2161 GATTATTCTTTTATTGTTTTTGACTGTTCCCTGTTTTTTTCTGTGACTGCTGTAACTTAAAGTTTTTGAAACTGAATTGC 2241 TTCAAATAAATTGAAGATTTGTTATAATGATTAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545214. RNA binding protein: AGO3. Condition:Control
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Disease | 81611.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM714644. RNA binding protein: AGO2. Condition:completeT1
"PAR-CLIP data was present in GSM714645. RNA binding protein: AGO2. Condition:completeT1
... - Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods. |
Article |
- Kishore S; Jaskiewicz L; Burger L; Hausser et al. - Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | hESCs (WA-09) |
Disease | 81611.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in SRR359787. RNA binding protein: AGO2. Condition:4-thiouridine
... - Lipchina I; Elkabetz Y; Hafner M; Sheridan et al., 2011, Genes & development. |
Article |
- Lipchina I; Elkabetz Y; Hafner M; Sheridan et al. - Genes & development, 2011
MicroRNAs are important regulators in many cellular processes, including stem cell self-renewal. Recent studies demonstrated their function as pluripotency factors with the capacity for somatic cell reprogramming. However, their role in human embryonic stem (ES) cells (hESCs) remains poorly understood, partially due to the lack of genome-wide strategies to identify their targets. Here, we performed comprehensive microRNA profiling in hESCs and in purified neural and mesenchymal derivatives. Using a combination of AGO cross-linking and microRNA perturbation experiments, together with computational prediction, we identified the targets of the miR-302/367 cluster, the most abundant microRNAs in hESCs. Functional studies identified novel roles of miR-302/367 in maintaining pluripotency and regulating hESC differentiation. We show that in addition to its role in TGF-beta signaling, miR-302/367 promotes bone morphogenetic protein (BMP) signaling by targeting BMP inhibitors TOB2, DAZAP2, and SLAIN1. This study broadens our understanding of microRNA function in hESCs and is a valuable resource for future studies in this area.
LinkOut: [PMID: 22012620]
|
Experimental Support 4 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | Prostate Tissue |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRX1760632. RNA binding protein: AGO2. Condition:AGO-CLIP-22RV1_C
... - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.). |
Article |
- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al. - Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
|
CLIP-seq Support 1 for dataset GSM545214 | |
---|---|
Method / RBP | PAR-CLIP / AGO3 |
Cell line / Condition | HEK293 / Control |
Location of target site | ENST00000533654.1 | 3UTR | ACUUUCUUAUCAAUCAUCUUACUGUGCAAUCA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM545216 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / miR-124 transfection |
Location of target site | ENST00000533654.1 | 3UTR | ACUUUCUUAUCAAUCAUCUUACUGUGCAAUCAA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM714644 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repA |
Location of target site | ENST00000533654.1 | 3UTR | GACUUUCUUAUCAAUCAUCUUACUGUGCAAUCAAAAUUAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
CLIP-seq Support 4 for dataset GSM714645 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repB |
Location of target site | ENST00000533654.1 | 3UTR | ACUUUCUUAUCAAUCAUCUUACUGUGCAAUCAAAAUUAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
CLIP-seq Support 5 for dataset SRR359787 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | hESCs (WA-09) / 4-thiouridine, RNase T1 |
Location of target site | ENST00000533654.1 | 3UTR | ACUUUCUUAUCAAUCAUCUUACUGUGCAAUCAAAAUUAGAGUACUUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22012620 / SRX103431 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
75 hsa-miR-16-2-3p Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT004488 | RARB | retinoic acid receptor beta | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT038707 | NUCKS1 | nuclear casein kinase and cyclin dependent kinase substrate 1 | ![]() |
1 | 1 | |||||||
MIRT057208 | PPIF | peptidylprolyl isomerase F | ![]() |
![]() |
2 | 4 | ||||||
MIRT058726 | RSBN1 | round spermatid basic protein 1 | ![]() |
![]() |
2 | 8 | ||||||
MIRT074502 | NFATC2IP | nuclear factor of activated T-cells 2 interacting protein | ![]() |
![]() |
2 | 4 | ||||||
MIRT081544 | ZNF431 | zinc finger protein 431 | ![]() |
![]() |
2 | 4 | ||||||
MIRT096893 | ERBB2IP | erbb2 interacting protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT105124 | MYC | MYC proto-oncogene, bHLH transcription factor | ![]() |
![]() |
2 | 2 | ||||||
MIRT107898 | PTAR1 | protein prenyltransferase alpha subunit repeat containing 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT109432 | KLHL15 | kelch like family member 15 | ![]() |
![]() |
2 | 6 | ||||||
MIRT166742 | PAPD7 | poly(A) RNA polymerase D7, non-canonical | ![]() |
![]() |
2 | 6 | ||||||
MIRT171257 | YWHAG | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma | ![]() |
![]() |
2 | 2 | ||||||
MIRT192760 | B2M | beta-2-microglobulin | ![]() |
![]() |
2 | 2 | ||||||
MIRT194905 | RBBP6 | RB binding protein 6, ubiquitin ligase | ![]() |
![]() |
2 | 8 | ||||||
MIRT215599 | SUB1 | SUB1 homolog, transcriptional regulator | ![]() |
![]() |
2 | 2 | ||||||
MIRT223632 | ATP6V1C1 | ATPase H+ transporting V1 subunit C1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT241605 | AMOTL1 | angiomotin like 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT291174 | SH3GLB1 | SH3 domain containing GRB2 like, endophilin B1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT444286 | ABCG2 | ATP binding cassette subfamily G member 2 (Junior blood group) | ![]() |
![]() |
2 | 2 | ||||||
MIRT463285 | ZFX | zinc finger protein, X-linked | ![]() |
![]() |
2 | 4 | ||||||
MIRT471759 | NUS1 | NUS1 dehydrodolichyl diphosphate synthase subunit | ![]() |
![]() |
2 | 8 | ||||||
MIRT479611 | CDC25A | cell division cycle 25A | ![]() |
![]() |
2 | 2 | ||||||
MIRT481497 | ARL6IP1 | ADP ribosylation factor like GTPase 6 interacting protein 1 | ![]() |
![]() |
2 | 8 | ||||||
MIRT483117 | SH3BP5 | SH3 domain binding protein 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT502279 | GRPEL2 | GrpE like 2, mitochondrial | ![]() |
![]() |
2 | 8 | ||||||
MIRT507838 | CCNT1 | cyclin T1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT508179 | MTRNR2L6 | MT-RNR2-like 6 | ![]() |
![]() |
2 | 4 | ||||||
MIRT510576 | UBE2D3 | ubiquitin conjugating enzyme E2 D3 | ![]() |
![]() |
2 | 6 | ||||||
MIRT517853 | RPS4X | ribosomal protein S4, X-linked | ![]() |
![]() |
2 | 4 | ||||||
MIRT521690 | PRKAA1 | protein kinase AMP-activated catalytic subunit alpha 1 | ![]() |
![]() |
2 | 8 | ||||||
MIRT525070 | FRK | fyn related Src family tyrosine kinase | ![]() |
![]() |
2 | 2 | ||||||
MIRT527082 | UBE2E3 | ubiquitin conjugating enzyme E2 E3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT529552 | EI24 | EI24, autophagy associated transmembrane protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT530426 | SULT1B1 | sulfotransferase family 1B member 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT533909 | TBC1D15 | TBC1 domain family member 15 | ![]() |
![]() |
2 | 2 | ||||||
MIRT536627 | IPO7 | importin 7 | ![]() |
![]() |
2 | 2 | ||||||
MIRT537647 | ERGIC2 | ERGIC and golgi 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT538512 | CLCN3 | chloride voltage-gated channel 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT539219 | ANP32E | acidic nuclear phosphoprotein 32 family member E | ![]() |
![]() |
2 | 6 | ||||||
MIRT539348 | AGO2 | argonaute 2, RISC catalytic component | ![]() |
![]() |
2 | 4 | ||||||
MIRT539954 | CCT4 | chaperonin containing TCP1 subunit 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT541208 | HOXA10 | homeobox A10 | ![]() |
![]() |
2 | 2 | ||||||
MIRT543216 | TMEM117 | transmembrane protein 117 | ![]() |
![]() |
2 | 2 | ||||||
MIRT543399 | DROSHA | drosha ribonuclease III | ![]() |
![]() |
2 | 2 | ||||||
MIRT546648 | RPS6KA5 | ribosomal protein S6 kinase A5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT546852 | RAB1A | RAB1A, member RAS oncogene family | ![]() |
![]() |
2 | 2 | ||||||
MIRT549917 | MRPS30 | mitochondrial ribosomal protein S30 | ![]() |
![]() |
2 | 2 | ||||||
MIRT552998 | USP46 | ubiquitin specific peptidase 46 | ![]() |
![]() |
2 | 2 | ||||||
MIRT555254 | PREPL | prolyl endopeptidase-like | ![]() |
![]() |
2 | 2 | ||||||
MIRT555956 | NRIP1 | nuclear receptor interacting protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT557095 | HOXA9 | homeobox A9 | ![]() |
![]() |
2 | 2 | ||||||
MIRT561396 | TUBB2A | tubulin beta 2A class IIa | ![]() |
![]() |
2 | 2 | ||||||
MIRT561654 | RNF219 | ring finger protein 219 | ![]() |
![]() |
2 | 2 | ||||||
MIRT563101 | PABPC4L | poly(A) binding protein cytoplasmic 4 like | ![]() |
![]() |
2 | 2 | ||||||
MIRT565979 | RNF44 | ring finger protein 44 | ![]() |
![]() |
2 | 2 | ||||||
MIRT572396 | CCDC14 | coiled-coil domain containing 14 | ![]() |
![]() |
2 | 2 | ||||||
MIRT574400 | TM9SF3 | transmembrane 9 superfamily member 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT607623 | VSNL1 | visinin like 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT610645 | CTGF | connective tissue growth factor | ![]() |
![]() |
2 | 2 | ||||||
MIRT623379 | LPP | LIM domain containing preferred translocation partner in lipoma | ![]() |
![]() |
2 | 2 | ||||||
MIRT624687 | AR | androgen receptor | ![]() |
![]() |
2 | 2 | ||||||
MIRT632089 | ALDH1A2 | aldehyde dehydrogenase 1 family member A2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT644216 | CBS | cystathionine-beta-synthase | ![]() |
![]() |
2 | 2 | ||||||
MIRT647841 | BID | BH3 interacting domain death agonist | ![]() |
![]() |
2 | 2 | ||||||
MIRT651649 | WASF2 | WAS protein family member 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT689064 | AGMAT | agmatinase | ![]() |
![]() |
2 | 2 | ||||||
MIRT698150 | TNPO1 | transportin 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT700516 | PTPN14 | protein tyrosine phosphatase, non-receptor type 14 | ![]() |
![]() |
2 | 2 | ||||||
MIRT704081 | DYRK2 | dual specificity tyrosine phosphorylation regulated kinase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT705970 | ACBD5 | acyl-CoA binding domain containing 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT715694 | COMMD3-BMI1 | COMMD3-BMI1 readthrough | ![]() |
![]() |
2 | 2 | ||||||
MIRT717184 | BMI1 | BMI1 proto-oncogene, polycomb ring finger | ![]() |
![]() |
2 | 2 | ||||||
MIRT724607 | AP3B1 | adaptor related protein complex 3 beta 1 subunit | ![]() |
![]() |
2 | 2 | ||||||
MIRT724854 | IGFBP5 | insulin like growth factor binding protein 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT725401 | LRIG2 | leucine rich repeats and immunoglobulin like domains 2 | ![]() |
![]() |
2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|